胃肠道癌患者接受免疫检查点抑制剂治疗期间的超进展：晚期肿瘤进展的自然过程？
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
作者信息
Wang Mo-Xuan, Gao Shu-Yue, Yang Fan, Fan Run-Jia, Yang Qin-Na, Zhang Tian-Lan, Qian Nian-Song, Dai Guang-Hai
机构信息
Department of Oncology, Chinese PLA Medical School, Beijing 100853, China.
Department of Oncology, Senior Department of Respiratory and Critical Care Medicine, The Eighth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
出版信息
World J Clin Oncol. 2022 Sep 24;13(9):729-737. doi: 10.5306/wjco.v13.i9.729.
Abstract
Immunotherapy has shown great promise in treating various types of malignant tumors. However, some patients with gastrointestinal cancer have been known to experience rapid disease progression after treatment, a situation referred to as hyperprogressive disease (HPD). This minireview focuses on the definitions and potential mechanisms of HPD, natural disease progression in gastrointestinal malignancies, and tumor immunological microenvironment.
摘要
免疫疗法在治疗各种类型的恶性肿瘤方面已显示出巨大的前景。然而，已知一些胃肠道癌患者在治疗后会出现疾病快速进展的情况，这种情况被称为超进展性疾病（HPD）。本综述聚焦于HPD的定义和潜在机制、胃肠道恶性肿瘤的自然疾病进展以及肿瘤免疫微环境。
相似文献
1
Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
World J Clin Oncol. 2022 Sep 24;13(9):729-737. doi: 10.5306/wjco.v13.i9.729.
2
Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.
Transl Lung Cancer Res. 2021 Jul;10(7):3276-3291. doi: 10.21037/tlcr-21-575.
3
Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.
J Clin Pharmacol. 2022 Sep;62(9):1059-1078. doi: 10.1002/jcph.2048. Epub 2022 Apr 19.
4
Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Curr Probl Cancer. 2021 Jun;45(3):100688. doi: 10.1016/j.currproblcancer.2020.100688. Epub 2020 Dec 9.
5
Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.
Front Nutr. 2022 Mar 25;9:810472. doi: 10.3389/fnut.2022.810472. eCollection 2022.
6
Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
Immunotherapy. 2019 Feb;11(3):167-175. doi: 10.2217/imt-2018-0126.
7
Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
Int J Cancer. 2021 Jul 15;149(2):277-286. doi: 10.1002/ijc.33429. Epub 2020 Dec 16.
8
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
Cancer Immunol Immunother. 2021 May;70(5):1491-1496. doi: 10.1007/s00262-020-02716-3. Epub 2020 Sep 14.
9
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Trends Cancer. 2020 Mar;6(3):181-191. doi: 10.1016/j.trecan.2020.01.005. Epub 2020 Feb 6.
10
Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody.
Front Immunol. 2021 Sep 29;12:749204. doi: 10.3389/fimmu.2021.749204. eCollection 2021.
本文引用的文献
1
Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Front Immunol. 2021 Dec 23;12:800630. doi: 10.3389/fimmu.2021.800630. eCollection 2021.
2
A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease.
Cell Biol Toxicol. 2023 Jun;39(3):1169-1180. doi: 10.1007/s10565-021-09672-3. Epub 2021 Nov 19.
3
Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.
Transl Lung Cancer Res. 2021 Jul;10(7):3276-3291. doi: 10.21037/tlcr-21-575.
4
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Gastric Cancer. 2022 Jan;25(1):235-244. doi: 10.1007/s10120-021-01237-x. Epub 2021 Aug 24.
5
Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Dis Markers. 2021 Jun 22;2021:6639366. doi: 10.1155/2021/6639366. eCollection 2021.
6
Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Front Immunol. 2021 May 31;12:608292. doi: 10.3389/fimmu.2021.608292. eCollection 2021.
7
The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity.
Nat Immunol. 2021 Apr;22(4):460-470. doi: 10.1038/s41590-021-00888-3. Epub 2021 Mar 25.
8
Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2021 Mar 1;4(3):e211136. doi: 10.1001/jamanetworkopen.2021.1136.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
IFN-γ and CD38 in Hyperprogressive Cancer Development.
Cancers (Basel). 2021 Jan 15;13(2):309. doi: 10.3390/cancers13020309.
Zotero 插件